{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:23:50Z","timestamp":1782833030519,"version":"3.54.5"},"reference-count":26,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Hypercholesterolemia in patients with nephrotic syndrome (NS) may predispose to cardiovascular events and alter kidney function. We aimed to evaluate statins efficiency in NS patients under immunosuppression using four endpoints: remission rate (RR), end-stage kidney disease (ESKD), major cardiovascular events (MACE), and thrombotic complications (VTE). Materials and Methods: We retrospectively examined the outcome at 24 months after diagnosis of 154 NS patients (age 53 (39\u201364) years, 64% male, estimated glomerular filtration rate (eGFR) 61.9 (45.2\u201381.0) mL\/min). During the follow-up, the lipid profile was evaluated at 6 months and at 1 and 2 years. Results: The median cholesterol level was 319 mg\/dL, and 83% of the patients received statins. Patients without statins (17%) had similar age, body mass index, comorbidities, blood lipids levels, NS severity, and kidney function. The most used statin was simvastatin (41%), followed by rosuvastatin (32%) and atorvastatin (27%). Overall, 79% of the patients reached a form of remission, 5% reached ESKD, 8% suffered MACE, and 11% had VTE. The mean time to VTE was longer in the statin group (22.6 (95%CI 21.7, 23.6) versus 20.0 (95%CI 16.5, 23.5) months, p 0.02). In multivariate analysis, statin therapy was not associated with better RR, kidney survival, or fewer MACE; however, the rate of VTE was lower in patients on statins (HR 2.83 (95%CI 1.02, 7.84)). Conclusions: Statins did not improve the remission rate and did not reduce the risk of MACE or ESKD in non-diabetic nephrotic patients. However, statins seemed to reduce the risk of VTE. Further randomized controlled studies are needed to establish statins\u2019 role in NS management.<\/jats:p>","DOI":"10.3390\/medicina59030512","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T05:18:43Z","timestamp":1678079923000},"page":"512","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Nephrotic Syndrome and Statin Therapy: An Outcome Analysis"],"prefix":"10.3390","volume":"59","author":[{"given":"Ruxandra","family":"Busuioc","sequence":"first","affiliation":[{"name":"Nephrology Department, University of Medicine and Pharmacy \u201cCarol Davila\u201d, 050474 Bucharest, Romania"},{"name":"Nephrology Department, \u201cDr Carol Davila\u201d Teaching Hospital of Nephrology, 010731 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7336-5874","authenticated-orcid":false,"given":"Gabriel","family":"\u0218tefan","sequence":"additional","affiliation":[{"name":"Nephrology Department, University of Medicine and Pharmacy \u201cCarol Davila\u201d, 050474 Bucharest, Romania"},{"name":"Nephrology Department, \u201cDr Carol Davila\u201d Teaching Hospital of Nephrology, 010731 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Stancu","sequence":"additional","affiliation":[{"name":"Nephrology Department, University of Medicine and Pharmacy \u201cCarol Davila\u201d, 050474 Bucharest, Romania"},{"name":"Nephrology Department, \u201cDr Carol Davila\u201d Teaching Hospital of Nephrology, 010731 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Zugravu","sequence":"additional","affiliation":[{"name":"Nephrology Department, University of Medicine and Pharmacy \u201cCarol Davila\u201d, 050474 Bucharest, Romania"},{"name":"Nephrology Department, \u201cDr Carol Davila\u201d Teaching Hospital of Nephrology, 010731 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Mircescu","sequence":"additional","affiliation":[{"name":"Nephrology Department, University of Medicine and Pharmacy \u201cCarol Davila\u201d, 050474 Bucharest, Romania"},{"name":"Nephrology Department, \u201cDr Carol Davila\u201d Teaching Hospital of Nephrology, 010731 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.kint.2016.02.026","article-title":"Disorders of lipid metabolism in nephrotic syndrome: Mechanisms and consequences","volume":"90","author":"Vaziri","year":"2016","journal-title":"Kidney Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1056\/NEJM199008303230905","article-title":"Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome","volume":"323","author":"Joven","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ki.1991.190","article-title":"Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria","volume":"40","author":"Warwick","year":"1991","journal-title":"Kidney Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ki.1995.73","article-title":"Metabolism of low density lipoproteins in nephrotic dyslipidemia: Comparison of hypercholesterolemia alone and combined hyperlipidemia","volume":"47","author":"Vega","year":"1995","journal-title":"Kidney Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.1993.292","article-title":"The increased risk of coronary heart disease associated with nephrotic syndrome","volume":"44","author":"Ordonez","year":"1993","journal-title":"Kidney Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/ndt\/gfz108","article-title":"Protein convertase subtilisin\/kexin type 9 biology in nephrotic syndrome: Implications for use as therapy","volume":"35","author":"Busuioc","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/ki.1993.358","article-title":"Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria","volume":"44","author":"Thomas","year":"1993","journal-title":"Kidney Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(88)90870-7","article-title":"Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome","volume":"2","author":"Rabelink","year":"1988","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1159\/000065021","article-title":"Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome","volume":"91","author":"Gheith","year":"2002","journal-title":"Nephron"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1046\/j.1523-1755.1999.07128.x","article-title":"Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group","volume":"71","author":"Olbricht","year":"1999","journal-title":"Kidney Int. Suppl."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1053\/j.ajkd.2008.07.010","article-title":"Statins for slowing kidney disease progression: An as yet unproven indication","volume":"52","author":"Tonelli","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/08923973.2021.1966033","article-title":"Transplantation and immunosuppression: A review of novel transplant-related immunosuppressant drugs","volume":"43","author":"Parlakpinar","year":"2021","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1046\/j.1523-1755.2002.00483.x","article-title":"Statin therapy improves brachial artery endothelial function in nephrotic syndrome","volume":"62","author":"Dogra","year":"2002","journal-title":"Kidney Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0272-6386(12)70179-8","article-title":"The nephrotic syndrome, lipids, and risk factors for cardiovascular disease","volume":"22","author":"Radhakrishnan","year":"1993","journal-title":"Am. J. Kidney Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.107.716951","article-title":"High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: Results from a large retrospective cohort study","volume":"117","author":"Mahmoodi","year":"2008","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJMcibr1209459","article-title":"Venous thrombosis in the nephrotic syndrome","volume":"368","author":"Loscalzo","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.thromres.2005.03.030","article-title":"Thromboembolic complications in the nephrotic syndrome: Pathophysiology and clinical management","volume":"118","author":"Singhal","year":"2006","journal-title":"Thromb. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ajh.10299","article-title":"Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase","volume":"72","author":"Longstaff","year":"2003","journal-title":"Am. J. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/0886022X.2022.2033265","article-title":"Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy","volume":"44","author":"Stefan","year":"2022","journal-title":"Ren. Fail."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1161\/01.ATV.6.2.203","article-title":"Increased fibrinogen binding to platelets from patients with familial hypercholesterolemia","volume":"6","author":"DiMinno","year":"1986","journal-title":"Arteriosclerosis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tcm.2013.07.003","article-title":"Hyperlipidemia, tissue factor, coagulation, and simvastatin","volume":"24","author":"Owens","year":"2014","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic Effects of Statins on the Cardiovascular System","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1538-7836.2004.00658.x","article-title":"Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction","volume":"2","author":"Kaba","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1161\/01.ATV.0000151647.14923.ec","article-title":"Statins and blood coagulation","volume":"25","author":"Undas","year":"2005","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1080\/0886022X.2021.1879853","article-title":"Statins can benefit patients with primary membranous nephropathy on venous thromboembolism","volume":"43","author":"Zou","year":"2021","journal-title":"Ren. Fail."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/3\/512\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:48:55Z","timestamp":1760122135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/3\/512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["medicina59030512"],"URL":"https:\/\/doi.org\/10.3390\/medicina59030512","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,6]]}}}